LIFECORE BIOMEDICAL, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
LIFECORE BIOMEDICAL, INC. (LFCR) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $4.63 per share for the 7-month period ending 2025-12-31, per its 10-KT filed 2026-03-16.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-03-16
- LIFECORE BIOMEDICAL, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2024-08-25 was $0.00, a 100.00% decline year-over-year.
- LIFECORE BIOMEDICAL, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2023-08-27 was $9.38.
- LIFECORE BIOMEDICAL, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $9.38, a 1.99% decline from fiscal 2023.
- LIFECORE BIOMEDICAL, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $9.57, a 1.24% decline from fiscal 2022.
- LIFECORE BIOMEDICAL, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2022 was $9.69.
- LIFECORE BIOMEDICAL, INC. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 7 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | $4.63 10-KT · filed 2026-03-16 | ||||
| 2024-11-24 | $0.00 10-Q · filed 2025-01-02 | ||||
| 2024-08-25 | $0.00 10-Q · filed 2024-10-04 | ||||
| 2024-05-26 | $9.38 10-K · filed 2024-08-26 | ||||
| 2024-02-25 | $9.38 10-Q · filed 2024-08-09 | ||||
| 2023-11-26 | $9.38 10-Q · filed 2024-08-09 | ||||
| 2023-08-27 | $9.38 10-Q · filed 2024-08-09 | ||||
| 2023-05-28 | $9.57 10-K · filed 2024-03-20 | ||||
| 2022-05-29 | $9.69 10-K · filed 2024-03-20 | ||||
| 2021-05-30 | $0.00 10-K/A · filed 2023-03-16 | ||||
| 2020-05-31 | $11.16 10-K/A · filed 2023-03-16 | ||||
| 2019-05-26 | $11.82 10-K · filed 2021-07-29 | ||||
| 2018-05-27 | $7.36 10-K · filed 2020-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |